CELF2, also called ETR3, has been identified as a novel risk factor associated with AD, particularly in individuals carrying the high-risk APOE ε4 allele, and it has also shown significant association with AD independent of APOE ε4, indicating its potential as a valuable therapeutic target for addressing underlying genetic causes of the disease (Tran, 2023). This evidence concerns the gene CELF2 and Alzheimer disease.